Research map: Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer

Back to the article

Papers in this map

  1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies · Brian David Lehmann · 2011 · 5674 citations · Cited by this paper
  2. Adenosine receptor signaling in vascular diseases: from molecular mechanisms to targeted therapeutics · 2026 · Related
  3. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease · Giampaolo Bianchini · 2016 · 3204 citations · Cited by this paper
  4. Macrophage FOLR2 drives liver fibrosis via intercellular engagement of TGFβRII · 2026 · Related
  5. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer · Shanu Modi · 2022 · 2707 citations · Cited by this paper
  6. Cardiomyocyte OTUD7b drives diabetic cardiomyopathy via deubiquitinating and stabilizing TAK1 · 2026 · Related
  7. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma · Torsten O. Nielsen · 2004 · 2681 citations · Cited by this paper
  8. Astrocytic adrenergic α2 receptor contributes to the mechanisms underlying the circadian rhythmicity of seizure susceptibility · 2026 · Related
  9. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation · Jennifer Keating Litton · 2018 · 2203 citations · Cited by this paper
  10. The solute carrier transporter SLCO5A1 as a novel therapeutic target for the treatment of myocardial infarction-induced heart failure · 2026 · Related
  11. ATR: an essential regulator of genome integrity · Karlene A. Cimprich · 2008 · 1821 citations · Cited by this paper
  12. Serum/glucocorticoid-regulated kinase 1 regulates vascular inflammation in atherosclerosis · 2026 · Related
  13. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer · Aditya Bardia · 2021 · 1674 citations · Cited by this paper
  14. METTL3 loss exacerbates colitis via m6A-dependent Slc39a8 regulation and epithelial lineage depletion · 2026 · Related
  15. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment · Ana Christina Garrido-Castro · 2019 · 1499 citations · Cited by this paper
  16. Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study · 2026 · Related
  17. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs · Giampaolo Bianchini · 2021 · 1438 citations · Cited by this paper
  18. Activation of peripheral muscarinic receptors rescues depressive-like behaviors via gut-brain-axis, involving parasympathetic excitation · 2026 · Related
  19. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer · Matthew D. Burstein · 2014 · 1437 citations · Cited by this paper
  20. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer · 2021 · Related
  21. Bafilomycin A1 Prevents Maturation of Autophagic Vacuoles by Inhibiting Fusion between Autophagosomes and Lysosomes in Rat Hepatoma Cell Line, H-4-II-E Cells. · Akitsugu Yamamoto · 1998 · 1335 citations · Cited by this paper
  22. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial · Peter Schmid · 2019 · 1230 citations · Cited by this paper
  23. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies · Yi‐Zhou Jiang · 2019 · 1139 citations · Cited by this paper
  24. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer · Matt I. Gross · 2014 · 1096 citations · Cited by this paper
  25. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline · Larissa A. Korde · 2021 · 1058 citations · Cited by this paper
  26. Androgen receptor: structure, role in prostate cancer and drug discovery · M-H. Tan · 2014 · 973 citations · Cited by this paper
  27. Triple negative breast cancer: Pitfalls and progress · Paola Zagami · 2022 · 848 citations · Cited by this paper
  28. Triple-negative breast cancer: disease entity or title of convenience? · Lisa A. Carey · 2010 · 792 citations · Cited by this paper
  29. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer · Mark E. Robson · 2019 · 786 citations · Cited by this paper
  30. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial · Sibylle Loibl · 2018 · 785 citations · Cited by this paper
  31. Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer · Ayca Gucalp · 2013 · 756 citations · Cited by this paper
  32. Genomic characterization of metastatic breast cancers · François Bertucci · 2019 · 756 citations · Cited by this paper
  33. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer · Constantia Pantelidou · 2019 · 747 citations · Cited by this paper
  34. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study · S. Loibl · 2019 · 713 citations · Cited by this paper
  35. Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer · Fergus J. Couch · 2014 · 700 citations · Cited by this paper
  36. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR · Philip M. Reaper · 2011 · 651 citations · Cited by this paper
  37. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer · Shaokun Shu · 2016 · 643 citations · Cited by this paper
  38. Targeting glutamine metabolism as a therapeutic strategy for cancer · Jonghwa Jin · 2023 · 556 citations · Cited by this paper
  39. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer · Feng Ye · 2023 · 556 citations · Cited by this paper

Source: OpenAlex (CC0)